The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Markus H. Moehler
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier; Transcenta; Triptych Health Partners
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; Nordic Group; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Lin Shen
No Relationships to Disclose
 
Marcelo Garrido
Consulting or Advisory Role - AstraZeneca; MSD; Roche
Speakers' Bureau - Bayer; Bristol-Myers Squibb; MERCK
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Carlos Gallardo
Consulting or Advisory Role - AstraZeneca; MSD; Roche
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Merck KGaA
Research Funding - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Roche
 
Lucjan S. Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
James M. Cleary
Honoraria - Blueprint Medicines; Incyte; Syros Pharmaceuticals
Research Funding - Apexigen; Arcus Biosciences; Arcus Biosciences; AstraZeneca; Bayer; BMS (Inst); BMS (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); SERVIER (Inst); Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Incyte; Roche
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Adaptimmune (Inst); Astellas Pharma; BeiGene (Inst); Bristol-Myers Squibb (Inst); Viracta Therapeutics; Zymeworks (Inst)
Research Funding - AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
 
Ricardo Elias Bruges Maya
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck; MSD Oncology; Novartis; Pfizer; Pfizer
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Pfizer; Tecnofarma; Tecnofarma
 
Michalis Karamouzis
Honoraria - Astellas Pharma; BMS; MSD; Pfizer Hellas; Roche; SERVIER
Speakers' Bureau - BMSi
Travel, Accommodations, Expenses - Ipsen
 
Tomasz Skoczylas
Research Funding - Bristol-Myers Squibb Japan
Travel, Accommodations, Expenses - Olympus
 
Arinilda Bragagnoli
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck
 
Tianshu Liu
No Relationships to Disclose
 
Mustapha Tehfe
Honoraria - Bristol-Myers Squibb; Merck KGaA; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Taiho Pharmaceutical
 
Kynan Feeney
No Relationships to Disclose
 
Rui Wang
No Relationships to Disclose
 
Raheel Nathani
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Master Clinician Alliance; Merck; Michael J. Hennessy Associates; Peerview; Research to Practice
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Guardant Health; Imedex; Imugene; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice